| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/03/2010 | EP2158919A1 Method for reducing postprandial glucose levels with a composition of whey protein and fiber |
| 03/03/2010 | EP2158918A1 Method for reducing postprandial glucose levels with a composition of whey protein |
| 03/03/2010 | EP1957484B1 Glucagon receptor antagonists, preparation and therapeutic uses |
| 03/03/2010 | EP1813289B1 Medicinal composition for treating cancer or diabetes |
| 03/03/2010 | EP1505973B1 Combinations for treating multiple myeloma |
| 03/03/2010 | EP1496920B1 Pharmaceutical composition containing an extract from barleria prionitis linn and its process of preparation |
| 03/03/2010 | EP1386908B1 Amine derivative with potassium channel regulatory function, its preparation and use |
| 03/03/2010 | EP1100801B1 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein |
| 03/03/2010 | CN101659639A Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 03/02/2010 | US7671252 Fad4, Fad5, Fad5-2, and Fad6, novel fatty acid desaturase family members and uses thereof |
| 03/02/2010 | US7671199 dual inhibitor of VEGFR and FGFR tyrosine kinases; cancer |
| 03/02/2010 | US7671180 Heparin binding protein for use in diagnosis, prvention and treatment of cell proliferative, liver, neurodegeneartive, inflammatory and pancreatic disorders; wound healing agents |
| 03/02/2010 | US7671174 appetite stimulants, antiobesity drugs, prolactin production inhibitors; drug screening; G-protein coupled (GPR) |
| 03/02/2010 | US7671090 Inhibitors of α4 mediated cell adhesion |
| 03/02/2010 | US7671087 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 03/02/2010 | US7671075 Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide |
| 03/02/2010 | US7671049 1-{3-[(6-amino-5-nitropyridin-2-yl)amino]propyl}-4-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-1H-pyrrole-3-carboxamide; Antidiabetic, hypotensive, antiischemic, anticarcinogenic agents; Alzheimer*s disease, obesity, polycystic ovary syndrome; brain, neurodegenerative and autoimmune diseases |
| 03/02/2010 | US7671047 Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| 03/02/2010 | US7670205 Crotch-possessing corrective garment |
| 02/28/2010 | CA2676955A1 Method for reducing postprandial blood glucose levels with a whey protein/fiber composition |
| 02/28/2010 | CA2676518A1 Whey protein pre-load |
| 02/25/2010 | WO2010022313A2 Processes for the preparation of sglt2 inhibitors |
| 02/25/2010 | WO2010022262A2 Methods for treating type i diabetes with leptin and leptin agonists |
| 02/25/2010 | WO2010022217A1 Combinations comprising bicyclic s1p lyase inhibitors |
| 02/25/2010 | WO2010022201A2 Folinic acid derivatives for promoting bone growth |
| 02/25/2010 | WO2010021879A2 Use of ultrarapid acting insulin |
| 02/25/2010 | WO2010021797A1 Condensed heterocyclic compounds having 5-ht6 receptor affinity |
| 02/25/2010 | WO2010021766A1 Hydroxybutyrate ester and medical use thereof |
| 02/25/2010 | WO2010021713A1 Use of d-ribose for fatigued subjects |
| 02/25/2010 | WO2010021351A1 Cycloalkylamine derivative |
| 02/25/2010 | WO2010020762A1 1,5-diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists |
| 02/25/2010 | WO2010020672A1 Novel phenyl-quinoline-carboxylic acid pyridine derivatives useful as modulators of nicotinic acetylcholine receptors |
| 02/25/2010 | WO2010020639A1 Arabinoxylans for modulating the barrier function of the intestinal surface |
| 02/25/2010 | WO2010020593A1 Treatment of an autoimmune disease using il-18 antagonists |
| 02/25/2010 | WO2010020308A1 7-azaindole derivatives |
| 02/25/2010 | WO2010020305A1 Oxadiazole derivatives for treating diabetes |
| 02/25/2010 | WO2010020004A1 Compositions and methods for inhibition of adipogenesis and the treatment of obesity |
| 02/25/2010 | WO2009149795A3 Heterocyclic cyclopropyl-substituted fxr binding compounds |
| 02/25/2010 | WO2009149058A3 Modified release niacin formulations |
| 02/25/2010 | WO2009149056A3 Combinations of niacin and an oxicam |
| 02/25/2010 | WO2009137795A3 Methods for treating endoplasmic reticulum (er) stress disorders |
| 02/25/2010 | US20100048714 Methods and Compositions Related to Inhibition of Ceramide Synthesis |
| 02/25/2010 | US20100048712 Acyclic Sulfamide Derivatives |
| 02/25/2010 | US20100048711 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 02/25/2010 | US20100048698 Macrocyclic diterpenes for treating conditions associated with protein kinase c |
| 02/25/2010 | US20100048666 Novel phenylacetic acid derivative |
| 02/25/2010 | US20100048663 Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents |
| 02/25/2010 | US20100048654 Use of valsartan or its metabolite to in hibit platelet aggregation |
| 02/25/2010 | US20100048641 Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases |
| 02/25/2010 | US20100048639 Oxadiazole derivates as s1p1 receptor agonists |
| 02/25/2010 | US20100048635 Use of collismycin and derivatives thereof as oxidative stress inhibitors |
| 02/25/2010 | US20100048632 Piperidine GPCR Agonists |
| 02/25/2010 | US20100048631 Piperidine GPCR Agonists |
| 02/25/2010 | US20100048627 synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| 02/25/2010 | US20100048625 Piperidine gpcr agonists |
| 02/25/2010 | US20100048617 Compounds |
| 02/25/2010 | US20100048600 such as trans-2-[3'-oxospiro [cyclohexane- 1,1'(3'H)-isobenzofuran]-4yl]-5-(2-pyridyl) imidazo[4,5-b]pyridine, exhibiting neuropeptide Y antagonistic effects, used for the treatment of cardiovascular, nervous system, metabolic, gastrointestinal, sexual and respiratory system disorders; pharmacokinetics |
| 02/25/2010 | US20100048595 Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota |
| 02/25/2010 | US20100048594 Use of cytohesin inhibitors for chemically inducing longevity |
| 02/25/2010 | US20100048588 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 02/25/2010 | US20100048584 Pyridyl derivatives and their use as therapeutic agents |
| 02/25/2010 | US20100048579 Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonists |
| 02/25/2010 | US20100048564 Fused bicyclic heteroaryl derivative |
| 02/25/2010 | US20100048558 Thienopyridines |
| 02/25/2010 | US20100048557 Triazolopyridine JAK Inhibitor Compounds and Methods |
| 02/25/2010 | US20100048550 Selective tr-beta 1 agonist |
| 02/25/2010 | US20100048545 Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity |
| 02/25/2010 | US20100048539 Compounds and compositions as protein kinase inhibitors |
| 02/25/2010 | US20100048537 Heteroaryl derivatives |
| 02/25/2010 | US20100048529 New 2-Azetidinone Derivatives Useful In The Treatment Of Hyperlipidaemic Conditions |
| 02/25/2010 | US20100048508 Mixture and method for reducing cholesterol using hydrophobic microparticles |
| 02/25/2010 | US20100048505 Composition Having Effect of Treating, Preventing, or Improving Diabetes or Diabetic Complication and Drink Comprising the Same |
| 02/25/2010 | US20100048484 Methods for treating diabetic wounds |
| 02/25/2010 | US20100048482 Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection |
| 02/25/2010 | US20100048468 Glp-1 compounds |
| 02/25/2010 | US20100048465 Peptide mimics of melanocyte stimulating hormone |
| 02/25/2010 | US20100048454 Antidiabetic oral insulin-biguanide combination |
| 02/25/2010 | US20100048453 Oxazole and thiazole ppar modulator |
| 02/25/2010 | US20100047364 Nutrient System for Individualized Responsive Dosing Regimens |
| 02/25/2010 | US20100047320 Oral polymeric membrane feruloyl esterase producing bacteria formulation |
| 02/25/2010 | US20100047259 Follistatin domain containing proteins |
| 02/25/2010 | US20100047221 Compositions comprising pyruvate alkyl esters and uses thereof |
| 02/25/2010 | US20100047220 Substances |
| 02/25/2010 | DE102008038222A1 Indazol-5-carbonsäurehydrazid-derivate Indazole-5-carboxylic acid derivatives |
| 02/25/2010 | DE102008038221A1 7-Azaindolderivate 7-azaindole derivatives |
| 02/25/2010 | DE102008038220A1 Oxadiazolderivate Oxadiazole |
| 02/25/2010 | CA2734769A1 Use of d-ribose for fatigued subjects |
| 02/25/2010 | CA2734720A1 Hydroxybutyrate ester and medical use thereof |
| 02/25/2010 | CA2734655A1 Combinations comprising bicyclic s1p lyase inhibitors |
| 02/25/2010 | CA2734442A1 Methods and compositions for oral administration of proteins |
| 02/25/2010 | CA2734398A1 7-azaindole derivatives |
| 02/25/2010 | CA2734397A1 Oxadiazole derivatives for the treatment of diabetes |
| 02/25/2010 | CA2734358A1 Treatment of an autoimmune disease using il-18 antagonists |
| 02/25/2010 | CA2734295A1 Processes for the preparation of sglt2 inhibitors |
| 02/25/2010 | CA2733593A1 Use of ultrarapid acting insulin |
| 02/25/2010 | CA2733551A1 Arabinoxylans for modulating the barrier function of the intestinal surface |
| 02/24/2010 | EP2157097A1 Specific binding agents of human angiopoietin-2 |
| 02/24/2010 | EP2157092A1 Remedy for diabetes |
| 02/24/2010 | EP2157091A1 Inhibitors of phosphatidylinositol 3-kinase |
| 02/24/2010 | EP2157090A1 Pyrazinamide compound |